1887

Abstract

An increased catalase activity in spp. has been suggested as a mechanism that reduces amphotericin B activity. Furthermore, resistance to antifungal agents like amphotericin B has been reported in some cancer patients undergoing chemotherapy treatment. In this study we analysed the influence of chemotherapy agents on catalase activity in , the major species involved in yeast infections. Eight strains of isolated from HIV-positive patients were exposed to cyclophosphamide, cytarabine, dacarbazine and methotrexate antineoplastic drugs at the concentrations used during therapy. Catalase activity was measured and compared to the control group. Very significant differences (<0·01) were found when was exposed to methotrexate (2 μg ml=4 μM). For cyclophosphamide (50 μg ml), cytarabine (1 μg ml) and dacarbazine (8 μg ml), no differences were found (>0·05) between the control and drug-exposed groups. Although more extensive studies are necessary, these data do suggest that the antineoplastic drug methotrexate contributes to the resistance to antifungal drug therapy by varying catalase activity.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46263-0
2006-03-01
2024-12-08
Loading full text...

Full text loading...

/deliver/fulltext/jmm/55/3/259.html?itemId=/content/journal/jmm/10.1099/jmm.0.46263-0&mimeType=html&fmt=ahah

References

  1. Abrahamsen T. G., Widing E., Glomstein A., Gaustad P. 1992; Disseminated fungal disease resistant to fluconazole treatment in a child with leukemia. Scand J Infect Dis 24:391–393 [CrossRef]
    [Google Scholar]
  2. Aebi H. 1984; Catalase in vitro . Method Enzymol 105:121–126
    [Google Scholar]
  3. Ahearn D. G., McGlohn M. S. 1984; In vitro susceptibilities of sucrose-negative Candida tropicalis , Candida lusitaniae , and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole and ketoconazole. J Clin Microbiol 19:412–416
    [Google Scholar]
  4. Batey M. A., Wright J. G., Azzabi A., Newell D. R., Lind M. J., Calvert A. H., Boddy A. V. 2002; Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Eur J Cancer 38:1081–1089 [CrossRef]
    [Google Scholar]
  5. Bradford M. M. 1976; A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72:248–254 [CrossRef]
    [Google Scholar]
  6. Brajtburg J., Elberg S., Kobayashi G. S., Medoff G. 1988; Interference with effects of amphotericin B on Candida albicans cells by 2-chloroethyl-1-nitrosoureas. Antimicrob Agents Chemother 32:327–330 [CrossRef]
    [Google Scholar]
  7. Conly J., Rennie R., Johson J., Farah S., Hellman L. 1992; Disseminated candidiasis due to amphotericin B-resistant Candida albicans . J Infect Dis 165:761–764 [CrossRef]
    [Google Scholar]
  8. Davies A., Brailsford S., Broadley K., Beighton D. 2002; Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. Palliat Med 16:527–531 [CrossRef]
    [Google Scholar]
  9. Dick J. D., Merz W. G., Saral R. 1980; Incidence of polyene resistant yeast recovered from clinical specimens. Antimicrob Agents Chemother 18:158–163 [CrossRef]
    [Google Scholar]
  10. Egorin M. J., Forrest A., Belani C. P., Ratain M. J., Abrams J. S., Van Echo D. A. 1989; A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 49:3129–3133
    [Google Scholar]
  11. Ghannoum M. A. 1986; Effects of antineoplastic agents on growth, morphology and metabolism of Torulopsis glabrata . Mycopathologia 95:175–181 [CrossRef]
    [Google Scholar]
  12. Lineweaver H., Burk D. 1934; The determination of enzyme dissociation constant. J Am Chem Soc 116:688
    [Google Scholar]
  13. Kerridge D., Nicholas R. D. 1986; Drug resistance in the opportunistic pathogens Candida albicans and C. glabrata . J Antimicrob Chemother 18:39–49
    [Google Scholar]
  14. Liliemark J., Peterson C. 1991; Pharmacokinetic optimization of anticancer therapy. Clin Pharmacokinet 21:213–231 [CrossRef]
    [Google Scholar]
  15. Morikawa N., Mori T., Abe T., Ghoda M., Takeyama M., Hori S. 1997; Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid. Ann Pharmacother 31:1153–1156
    [Google Scholar]
  16. Nakagawa Y., Kanbe T., Mizuguchi I. 2003; Disruption of the human pathogenic yeast Candida albicans catalase gene decreased survival in mouse-model infection and elevated susceptibility to higher temperature and to detergents. Microbiol Immunol 47:395–403 [CrossRef]
    [Google Scholar]
  17. Nolte F. S., Parkinson T., Falconer D. J., Dix S., Williams J., Gilmore C., Geller R., Wingard J. R. 1997; Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 44:196–199
    [Google Scholar]
  18. Salonen J. H., Richardson M. D., Gallacher K., Issakainen J., Helenius H., Lehtonen O. P., Nikoskelainen J. 2000; Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae . J Hosp Infect 45:293–301 [CrossRef]
    [Google Scholar]
  19. Sarachek A., Henderson L. A. 1991; Modification of responses of Candida albicans to cisplatin by membrane damaging antimycotic agents. Mycoses 34:177–182
    [Google Scholar]
  20. Sokol-Anderson M., Brajtburg J., Medoff G. 1986; Amphotericin B induced oxidative damage and killing of Candida albicans . J Infect Dis 154:76–83 [CrossRef]
    [Google Scholar]
  21. Sokol-Anderson M., Sligh J. E., Elberg S., Brajtburg J., Kobayashi G. S., Medoff G. 1988; Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother 32:702–705 [CrossRef]
    [Google Scholar]
  22. Vanden Bossche H., Marichal P., Odds C. F. 1994; Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2:393–400 [CrossRef]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.46263-0
Loading
/content/journal/jmm/10.1099/jmm.0.46263-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error